Parallax Volatility Advisers
NTLA icon

Parallax Volatility Advisers’s Intellia Therapeutics NTLA Stock Holding History

Parallax Volatility Advisers’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-35,994
Closed -$740K – 2237
2024
Q3 		$740K Buy
+35,994
New +$830K ﹤0.01% 1431
2023
Q2 		– Sell
-25,005
Closed -$932K – 2741
2023
Q1 		$932K Hold
25,005
– – ﹤0.01% 1534
2022
Q4 		$872K Buy
25,005
+21,108
+542% +$1M ﹤0.01% 1708
2022
Q3 		$218K Sell
3,897
-26,239
-87% -$1.63M ﹤0.01% 2285
2022
Q2 		$1.56M Buy
+30,136
New +$1.53M ﹤0.01% 1457
2021
Q4 		– Sell
-22
Closed -$3K – 2184
2021
Q3 		$3K Buy
+22
New +$3.33K ﹤0.01% 1947
2020
Q4 		– Sell
-8,900
Closed -$177K – 3081
2020
Q3 		$177K Buy
+8,900
New +$186K ﹤0.01% 2586
2018
Q3 		– Sell
-10,595
Closed -$290K – 3254
2018
Q2 		$290K Buy
+10,595
New +$257K ﹤0.01% 1353
2018
Q1 		– Sell
-2,142
Closed -$41K – 3592
2017
Q4 		$41K Buy
+2,142
New +$49.5K ﹤0.01% 3325

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Parallax Volatility Advisers's NTLA Position: Q4 2024 in Review

Parallax Volatility Advisers sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 35,994 shares — an estimated $740K sold.

Parallax Volatility Advisers first reported a position in NTLA in Q4 2017 and held it in 9 quarters. The position peaked at $1.56M in Q2 2022. 293 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Parallax Volatility Advisers reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Parallax Volatility Advisers sold 35,994 Intellia Therapeutics shares in Q4 2024, an estimated $740K.
  • Parallax Volatility Advisers first reported a position in Intellia Therapeutics in Q4 2017 and held it in 9 quarters.
  • Parallax Volatility Advisers's Intellia Therapeutics position peaked at $1.56M in Q2 2022.
  • 293 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Parallax Volatility Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.